Gennex Laboratories Limited (BOM:531739)
India
· Delayed Price · Currency is INR 12.07
-0.50 (-3.98%)
At close: May 9, 2025
Gennex Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,311 | 867.14 | 656.03 | 612.14 | 596.49 | 556.17 | Upgrade
|
| Other Revenue | - | - | - | - | - | 6.14 | Upgrade
|
| Revenue | 1,311 | 867.14 | 656.03 | 612.14 | 596.49 | 562.31 | Upgrade
|
| Revenue Growth (YoY) | 82.39% | 32.18% | 7.17% | 2.62% | 6.08% | -0.19% | Upgrade
|
| Cost of Revenue | 899.54 | 493.58 | 402.92 | 384.15 | 359.29 | 339.64 | Upgrade
|
| Gross Profit | 411.27 | 373.57 | 253.11 | 227.98 | 237.2 | 222.67 | Upgrade
|
| Selling, General & Admin | 74.93 | 78.91 | 80.63 | 73.48 | 74.36 | 71.38 | Upgrade
|
| Other Operating Expenses | 143.27 | 120.79 | 122.77 | 99.74 | 96.23 | 112.16 | Upgrade
|
| Operating Expenses | 234.98 | 223.38 | 212.6 | 181.1 | 179.4 | 193.6 | Upgrade
|
| Operating Income | 176.29 | 150.18 | 40.51 | 46.88 | 57.8 | 29.07 | Upgrade
|
| Interest Expense | -31.41 | -30.76 | -13.54 | -8.77 | -7.44 | -7.54 | Upgrade
|
| Interest & Investment Income | 37.95 | 37.95 | 26.61 | 9 | 0.54 | 0.79 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.76 | 1.76 | 4.15 | 3.79 | 3.44 | 2.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 37.1 | - | 5.5 | -0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 221.68 | 159.13 | 63.23 | 50.9 | 54.34 | 24.37 | Upgrade
|
| Gain (Loss) on Sale of Assets | 5.79 | 5.79 | 0.5 | 0.03 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -3.71 | 1.09 | Upgrade
|
| Pretax Income | 227.47 | 164.92 | 63.73 | 50.94 | 50.62 | 25.49 | Upgrade
|
| Income Tax Expense | 31.57 | 33.17 | 14.52 | 11.7 | 10.24 | 6.92 | Upgrade
|
| Net Income | 188.46 | 131.75 | 49.21 | 39.23 | 40.38 | 18.56 | Upgrade
|
| Net Income to Common | 188.46 | 131.75 | 49.21 | 39.23 | 40.38 | 18.56 | Upgrade
|
| Net Income Growth | 75.86% | 167.74% | 25.43% | -2.85% | 117.53% | -16.41% | Upgrade
|
| Shares Outstanding (Basic) | 219 | 187 | 146 | 127 | 127 | 127 | Upgrade
|
| Shares Outstanding (Diluted) | 249 | 217 | 154 | 127 | 127 | 127 | Upgrade
|
| Shares Change (YoY) | 57.04% | 40.48% | 21.94% | - | - | - | Upgrade
|
| EPS (Basic) | 0.86 | 0.71 | 0.34 | 0.31 | 0.32 | 0.15 | Upgrade
|
| EPS (Diluted) | 0.76 | 0.61 | 0.32 | 0.31 | 0.32 | 0.15 | Upgrade
|
| EPS Growth | 11.98% | 90.60% | 2.86% | -2.78% | 117.39% | -16.41% | Upgrade
|
| Free Cash Flow | - | -466.86 | -161.1 | 103.14 | -15.16 | -19.66 | Upgrade
|
| Free Cash Flow Per Share | - | -2.15 | -1.04 | 0.81 | -0.12 | -0.15 | Upgrade
|
| Gross Margin | 31.37% | 43.08% | 38.58% | 37.24% | 39.77% | 39.60% | Upgrade
|
| Operating Margin | 13.45% | 17.32% | 6.17% | 7.66% | 9.69% | 5.17% | Upgrade
|
| Profit Margin | 14.38% | 15.19% | 7.50% | 6.41% | 6.77% | 3.30% | Upgrade
|
| Free Cash Flow Margin | - | -53.84% | -24.56% | 16.85% | -2.54% | -3.50% | Upgrade
|
| EBITDA | 210.83 | 173.86 | 49.7 | 54.76 | 66.6 | 39.12 | Upgrade
|
| EBITDA Margin | 16.08% | 20.05% | 7.58% | 8.95% | 11.17% | 6.96% | Upgrade
|
| D&A For EBITDA | 34.54 | 23.68 | 9.19 | 7.88 | 8.81 | 10.05 | Upgrade
|
| EBIT | 176.29 | 150.18 | 40.51 | 46.88 | 57.8 | 29.07 | Upgrade
|
| EBIT Margin | 13.45% | 17.32% | 6.17% | 7.66% | 9.69% | 5.17% | Upgrade
|
| Effective Tax Rate | 13.88% | 20.11% | 22.79% | 22.98% | 20.23% | 27.16% | Upgrade
|
| Revenue as Reported | 1,397 | 916.2 | 695.56 | 625.95 | 601.73 | 565.69 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.